Supernus Pharmaceuticals | SUPN - Ebitda

Aktienkurs
49.76
Täglich Wechseln
-0.63 -1.25%
Monatlich
-0.60%
Jährlich
54.44%
Q2 Prognose
48.70




Ebitda Veränderung Datum
Abbott USD 3.27B 178M 2025-12
ANI Pharmaceuticals USD 65.36M 5.76M 2025-12
Aurora Cannabis CAD 18.48M 3.11M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Canopy Growth CAD -2.87M 19.49M 2025-12
Cara Therapeutics USD -2.39M 3.16M 2025-03
Corcept Therapeutics USD 4.2M 6.5M 2025-12
Eisai JPY 30.1B 6.62B 2025-12
Eli Lilly USD 7.88B 378.1M 2025-09
Novo Nordisk DKK 37.3B 5.86B 2025-12
Pacira USD 38.71M 10.65M 2025-12
Perrigo USD 258.8M 37.3M 2025-09
Pfizer USD 6.08B 351M 2025-09
Supernus Pharmaceuticals USD 48.5M 6.6M 2025-12
United Therapeutics USD 379.5M 83.4M 2025-12
Xeris Pharmaceuticals USD 25.09M 7.67M 2025-12